Table 3 Assumed specificity and sensitivity of TST and IGRA in cost-effectiveness studies depending on different countries
From: Systematic review of cost and cost-effectiveness of different TB-screening strategies
Country | Specificity | Sensitivity | |||
|---|---|---|---|---|---|
TST/BCG | QFT/ (T-SPOT) | ||||
No | Yes | TST | QFT/ (T-SPOT) | ||
Canada 2007 [23] | 98% | 60% | 98% | 95% | 95% |
Canada 2008 [22] | 99% | 62% | 96% | 99% | 99% |
Japan 2008 [24] | 98% | ≥ 15%* | 96% | 71% | 76% |
USA 2009 [25] | 98% | 70% | 100% | 67% | 76% |
Germany 2007 [27] | 90% | 60% | 100% | 90% | 90% |
Switzerland 2007 [28] | 34% | 34% | - | 88% | 95% |
UK 2010 [21] | - | 80% | 95% | 85% | 89% (100%) |
France 2010 [26] | - | 60% | 96% | 73% | 76% |